Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Boucher

Showing results (431-440 of 595) with videos related to

Pageof 60
Sort By:
The Journal of Infectious Diseases|January 1, 1992
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjectsC A Boucher, E O'Sullivan, J W Mulder, et al.
Autoimmunity|January 1, 1992
Antibodies in the serum of patients with autoimmune thyroid disorders react with a recombinant 98 amino acid fragment of a full length 64 kDa eye muscle membrane protein which is also expressed in the thyroidZ G Zhang, Q Dong, P Rodien, et al.
Lancet (London, England)|July 7, 1999
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trialJ Durant, P Clevenbergh, P Halfon, et al.
Genomics|May 16, 2001
Characterization of the human Xq21.3/Yp11 homology block and conservation of organization in primatesC A Sargent, C A Boucher, P Blanco, et al.
Archives of Internal Medicine|July 1, 2004
A randomized trial of Chinese herbal medicines for the treatment of symptomatic hepatitis CMrudula Jakkula, Tacey A Boucher, Ulrich Beyendorff, et al.
The Journal of Infectious Diseases|August 1, 1997
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivoM Nijhuis, R Schuurman, D de Jong, et al.
AIDS Research and Human Retroviruses|August 26, 1998
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected personsS M Bruisten, P Reiss, A E Loeliger, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1996
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assayC A Boucher, W Keulen, T van Bommel, et al.
The Journal of Infectious Diseases|October 1, 1996
Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysisA B van 't Wout, M D de Jong, N A Kootstra, et al.
AIDS (London, England)|September 26, 1997
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatmentM D de Jong, R J de Boer, F de Wolf, et al.
Pageof 60

Showing results (431-440 of 595) with videos related to

Sort By:
Pageof 60
The Journal of Infectious Diseases|January 1, 1992
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjectsC A Boucher, E O'Sullivan, J W Mulder, et al.
Autoimmunity|January 1, 1992
Antibodies in the serum of patients with autoimmune thyroid disorders react with a recombinant 98 amino acid fragment of a full length 64 kDa eye muscle membrane protein which is also expressed in the thyroidZ G Zhang, Q Dong, P Rodien, et al.
Lancet (London, England)|July 7, 1999
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trialJ Durant, P Clevenbergh, P Halfon, et al.
Genomics|May 16, 2001
Characterization of the human Xq21.3/Yp11 homology block and conservation of organization in primatesC A Sargent, C A Boucher, P Blanco, et al.
Archives of Internal Medicine|July 1, 2004
A randomized trial of Chinese herbal medicines for the treatment of symptomatic hepatitis CMrudula Jakkula, Tacey A Boucher, Ulrich Beyendorff, et al.
The Journal of Infectious Diseases|August 1, 1997
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivoM Nijhuis, R Schuurman, D de Jong, et al.
AIDS Research and Human Retroviruses|August 26, 1998
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected personsS M Bruisten, P Reiss, A E Loeliger, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1996
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assayC A Boucher, W Keulen, T van Bommel, et al.
The Journal of Infectious Diseases|October 1, 1996
Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysisA B van 't Wout, M D de Jong, N A Kootstra, et al.
AIDS (London, England)|September 26, 1997
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatmentM D de Jong, R J de Boer, F de Wolf, et al.
Pageof 60